Log in to your account:
Baird Upgrades Regeneron Pharma (REGN) to Outperform
August 7, 2019 4:28 AM
Baird analyst Brian Skorney upgraded Regeneron Pharma (NASDAQ: REGN) from Neutral to Outperform with a price target of $410.00.The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)